Thus, this study aims to analyze the 3-year time to relapse (TTR) and OS in 120 melanoma cases with stage IIC/III/IV in the adjuvant setting, treated with anti-PD-1 Abs or the combination of dabrafenib plus trametinib. This evidence concerns the gene PDCD1 and melanoma.